HARTMANN’s dynamic growth in previous quarters slows noticeably in first quarter of 2021

• Key financial indicators: organic sales growth of +2.0% compared to the first quarter of 2020, but lower than in the fourth quarter of 2020
• Outlook 2021: Management Board confirms forecast for the year 2021

Heidenheim, April 30, 2021. The coronavirus pandemic remains the dominant issue in the current financial year for HARTMANN's European core sales markets. The growth in sales seen over the course of the extraordinary year 2020, however, did not continue. Sales increases in the Infection Management segment compensated for a declining development in all other segments.

• Group: Overall, HARTMANN achieved organic sales growth of +2.0%. Sales revenues across all business segments amounted to EUR 593.3 million. If exchange rate effects as well as acquisitions and divestments are included, the Group recorded a sales decline of -1.7%. Adjusted EBITDA amounted to EUR 82.6 million. The earnings momentum slowed compared to the last quarter of 2020.
• Wound Management: The Wound Management segment remained negatively impacted by a reduction in elective surgeries, as well as fewer visits to doctors, among other things. There is less demand for traditional wound products in particular. However, modern wound management concepts defied this trend and developed positively.
• Infection Management: The development in the Infection Management segment is attributable to a strong demand for personal protective equipment. However, the business with disinfection products declined significantly due to customers building up large inventories and a general decline in market demand.
• Incontinence Management: Room occupancy rates in hospitals and nursing homes remained at a low level. In addition, there was no significant stockpiling by customers comparable to the first quarter of 2020. Both factors led to a decline in sales of products from the Incontinence Management segment.
• Other Group Activities: In the Other Group Activities segment, the pandemic is causing declining sales - at KOB due to lower demand for products for sports injuries, and at CMC Consumer Medical Care due to generally low demand for cosmetic products. Kneipp, on the other hand, continued catering very well to the trend of greater health awareness.

HARTMANN assumes that the pandemic will continue to influence the course of business. As the further course of events remains unclear, there is still a high degree of uncertainty in the prognosis for financial year 2021. Against this backdrop, the Company confirms the outlook for financial year 2021 as published in the Annual Report with a moderate organic decline in sales and a declining adjusted EBITDA of EUR 210 to 260 million.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” HARTMANN generated sales of EUR 2.3 billion in the 2023 financial year. Founded in 1818, the Company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customer-oriented and passionate team.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.